The course and determinants of post-traumatic stress over 12 months after hospitalization for COVID-19.
COVID-19
PCL-5 questionnaire
cohort
follow-up
medium-term
post-traumatic stress disorder (PTSD)
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
04
2022
accepted:
24
06
2022
entrez:
1
8
2022
pubmed:
2
8
2022
medline:
2
8
2022
Statut:
epublish
Résumé
To assess the trajectory of symptoms and symptom-defined post-traumatic stress disorder (PTSD) from 1.5 to 12 months after hospitalization for COVID-19 and determine risk factors for persistent symptoms and PTSD. This was a prospective cohort study of consecutive patients discharged after hospitalization for COVID-19 before 1 June 2020 in six hospitals in Southern Norway. Symptom-defined PTSD was assessed by the post-traumatic stress disorder (PTSD) checklist for DSM-5 (PCL-5) at 1.5, 3 and/or 12 months after hospitalization, using DSM-5 criteria. Changes in PCL-5 symptom score and the prevalence of PTSD were analyzed with multivariable mixed models. In total, 388 patients were discharged alive, and 251 (65%) participated. Respondents had a mean (SD) age of 58.4 (14.2) years, and 142 (57%) were males. The prevalence of symptom-defined PTSD was 14, 8, and 9% at 1.5, 3, and 12 months, respectively. WHO disease severity for COVID-19 was not associated with PCL-5 scores. Female sex, lower age and non-Norwegian origin were associated with higher PCL-5 scores. The odds ratio (OR) (95%CI) for PTSD was 0.32 (0.12 to 0.83, The level of PTSD symptoms decreased from 1.5 to 3 months after hospitalization, but did not decrease further to 12 months, and there was no association between PTSD symptoms and COVID-19 disease severity.
Identifiants
pubmed: 35911221
doi: 10.3389/fpsyt.2022.931349
pmc: PMC9334651
doi:
Types de publication
Journal Article
Langues
eng
Pagination
931349Informations de copyright
Copyright © 2022 Stavem, Heir, Dammen, Brønstad, Lerum, Durheim, Lund, Aarli and Einvik.
Références
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Crit Care Med. 2015 May;43(5):1121-9
pubmed: 25654178
PLoS One. 2020 Oct 14;15(10):e0239570
pubmed: 33052920
Front Med (Lausanne). 2022 May 11;9:854788
pubmed: 35646985
J Rehabil Med. 2020 May 25;52(5):jrm00063
pubmed: 32449782
Brain Behav Immun. 2020 Oct;89:594-600
pubmed: 32738287
Mol Psychiatry. 2021 Dec;26(12):7475-7480
pubmed: 34285348
J Psychiatr Res. 2021 Nov 22;145:118-124
pubmed: 34894521
Panminerva Med. 2021 Jun 01;:
pubmed: 34060280
Brain Behav Immun. 2021 Oct;97:328-348
pubmed: 34339806
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jul 13;109:110236
pubmed: 33373680
J Clin Psychiatry. 2020 Dec 8;82(1):
pubmed: 33296149
J Affect Disord. 2022 Feb 15;299:52-59
pubmed: 34800571
Clin Psychol Rev. 2014 Apr;34(3):249-55
pubmed: 24681171
Front Psychiatry. 2022 Apr 08;13:863698
pubmed: 35463490
PLoS One. 2021 Aug 11;16(8):e0255774
pubmed: 34379644
BMC Public Health. 2020 May 15;20(1):605
pubmed: 32410603
JAMA Psychiatry. 2021 May 1;78(5):567-569
pubmed: 33599709
Brain Behav Immun. 2021 May;94:138-147
pubmed: 33639239
Front Psychiatry. 2021 Mar 31;12:602244
pubmed: 33868043
J Trauma Stress. 2015 Dec;28(6):489-98
pubmed: 26606250
JAMA. 2021 Apr 20;325(15):1525-1534
pubmed: 33729425
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
J Neurovirol. 2021 Feb;27(1):154-159
pubmed: 33528827
Int J Environ Res Public Health. 2021 Feb 20;18(4):
pubmed: 33672759
J Gen Intern Med. 2021 Jun;36(6):1702-1707
pubmed: 33782888
Sci Rep. 2021 Nov 22;11(1):22666
pubmed: 34811387
Qual Life Res. 2022 May;31(5):1401-1414
pubmed: 34580823
Brain Behav Immun Health. 2021 Oct;16:100315
pubmed: 34345869
Emerg Infect Dis. 2005 Aug;11(8):1297-300
pubmed: 16102324
Eur Respir J. 2021 Jun 24;57(6):
pubmed: 33795319
BMJ. 2020 May 22;369:m1985
pubmed: 32444460